uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases
uBriGene Biosciences, a China-based advanced therapy medicinal product (ATMP) CDMO, has entered a strategic partnership...
FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement
The U.S. Food and Drug Administration (FDA) announced decisive regulatory action to restrict GLP-1 active...
China’s NHSA Launches Reference Drug Pre-Communication System to Streamline Reimbursement Pathway
The National Healthcare Security Administration (NHSA) has released the “Reference Drugs Pre-communication Measures (Trial)”, establishing...
AstraZeneca Reports 8% Revenue Growth to $58.7 Billion in 2025; Oncology Leads with 17% Surge
AstraZeneca PLC (AZ, NASDAQ: AZN) delivered strong 2025 financial results, with total revenues rising 8% year-on-year...
Gilead Reports 2025 Revenue Growth to $29.4 Billion on HIV Strength; Veklury Plunges 49%
Gilead Sciences, Inc. (NASDAQ: GILD) announced fourth quarter and full-year 2025 financial results, with total revenues...
Pfizer’s Cresemba Wins NMPA Pediatric Approval for Invasive Fungal Infections
Pfizer Inc. (NYSE: PFE) announced that the National Medical Products Administration (NMPA) has approved an indication...
Eli Lilly’s Omvoh Wins NMPA Approval for Crohn’s Disease and Ulcerative Colitis in China
The National Medical Products Administration (NMPA) has approved Eli Lilly and Company’s (NYSE: LLY) Omvoh (mirikizumab),...
China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million
China Resources Pharmaceutical Group Co., Ltd. (HKG: 3320) announced plans to sell a 17.87% stake in...
Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary Changchun GeneScience...
Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder
Sanofi (NASDAQ: SNY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device
Hangzhou Tangji Medical Technology Co., Ltd. has filed its IPO prospectus with the Hong Kong...
Eisai Biogen’s LEQEMBI Subcutaneous Autoinjector Wins NMPA Priority Review in China
Eisai Co., Ltd. and Biogen Inc. (NASDAQ: BIIB) announced that the Biologics License Application (BLA) for...
Takeda Enters $1.7 Billion AI Drug Discovery Partnership with Iambic Therapeutics
Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) has entered a multi-year strategic agreement with Iambic Therapeutics,...
Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China
Hemony Pharmaceutical Co., Ltd. has entered a strategic partnership with Insud Pharma, a leading Spanish...
Overseas Pharma Partners with South American Pharma Group on Global Extended-Release Drug Development
Overseas Pharmaceuticals Ltd (OPL), a China-based specialty pharmaceutical company, has entered a product development and...
Xianju Pharmaceutical and Adamerck Grant Aspen China Rights to Aomeikesong Neuromuscular Reversal Agent
Zhejiang Xianju Pharmaceutical Co., Ltd. (SHE: 002332) and Hangzhou Adamerck Pharmlabs Inc. have entered a...
Zhendong Pharmaceutical Secures China Promotion Rights to Ferring’s Sodium Picosulfate
Shanxi Zhendong Pharmaceutical Co., Ltd. (SHE: 300158) has entered a strategic partnership with Ferring Pharmaceuticals...
GenAssist Therapeutic Partners with Indian DART Foundation on Duchenne Muscular Dystrophy Base Editing
Suzhou GenAssist Therapeutic Co., Ltd. has signed a Memorandum of Understanding (MoU) with India’s Dystrophy...
Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera for $584.5 Million
Foresee Pharmaceuticals has entered an exclusive global licensing agreement with Primevera Therapeutics, a German biotech...
Formosa Pharmaceuticals Licenses APP13007 Eye Drops to Samil Pharma for South Korea Market
Formosa Pharmaceuticals, Inc. (TPE: 6838) has entered an exclusive licensing agreement with Samil Pharmaceuticals Co.,...